{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(6)"],"submitter":["Pantalone KM"],"funding":["Eli Lilly and Company"],"pubmed_abstract":["Aims
To assess efficacy and safety of dulaglutide 1.5 mg combined with insulin, categorized by subgroups of baseline glycated haemoglobin (HbA1c; ≤9% and >9% [≤74.9 and >74.9 mmol/mol]), age (<65 and ≥65 years), and duration of diabetes (<10 and ≥10 years) at 6 months in patients with type 2 diabetes (T2D).Materials and methods
This pooled analysis was conducted in a population of patients with T2D with similar baseline characteristics who were included in the AWARD-4 and AWARD-9 clinical trials and randomized to dulaglutide 1.5 mg (pooled mean baseline age 59 years, duration of diabetes 13 years, HbA1c 8.4% [68.3 mmol/mol]). Weight and hypoglycaemia were analysed by individual trial. In AWARD-4, dulaglutide plus lispro three times daily was assessed against glargine plus l"],"journal":["Diabetes, obesity & metabolism"],"pagination":["1461-1469"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5969314"],"repository":["biostudies-literature"],"pubmed_title":["Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration."],"pmcid":["PMC5969314"],"pubmed_authors":["Yu M","Patel H","Pantalone KM","Fernandez Lando L"],"additional_accession":[]},"is_claimable":false,"name":"Dulaglutide 1.5 mg as an add-on option for patients uncontrolled on insulin: Subgroup analysis by age, duration of diabetes and baseline glycated haemoglobin concentration.","description":"Aims
To assess efficacy and safety of dulaglutide 1.5 mg combined with insulin, categorized by subgroups of baseline glycated haemoglobin (HbA1c; ≤9% and >9% [≤74.9 and >74.9 mmol/mol]), age (<65 and ≥65 years), and duration of diabetes (<10 and ≥10 years) at 6 months in patients with type 2 diabetes (T2D).Materials and methods
This pooled analysis was conducted in a population of patients with T2D with similar baseline characteristics who were included in the AWARD-4 and AWARD-9 clinical trials and randomized to dulaglutide 1.5 mg (pooled mean baseline age 59 years, duration of diabetes 13 years, HbA1c 8.4% [68.3 mmol/mol]). Weight and hypoglycaemia were analysed by individual trial. In AWARD-4, dulaglutide plus lispro three times daily was assessed against glargine plus l","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Jun","modification":"2025-04-22T09:51:47.205Z","creation":"2019-03-26T23:39:30Z"},"accession":"S-EPMC5969314","cross_references":{"pubmed":["29430801"],"doi":["10.1111/dom.13252"]}}